ATE456558T1 - Gabanerge modulatoren - Google Patents

Gabanerge modulatoren

Info

Publication number
ATE456558T1
ATE456558T1 AT04763813T AT04763813T ATE456558T1 AT E456558 T1 ATE456558 T1 AT E456558T1 AT 04763813 T AT04763813 T AT 04763813T AT 04763813 T AT04763813 T AT 04763813T AT E456558 T1 ATE456558 T1 AT E456558T1
Authority
AT
Austria
Prior art keywords
gabanergic
modulators
gabanergic modulators
Prior art date
Application number
AT04763813T
Other languages
English (en)
Inventor
Xiao-Fa Lin
David Loughhead
Sanja Novakovic
Counde O'yang
David Putman
Michael Soth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE456558T1 publication Critical patent/ATE456558T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04763813T 2003-08-14 2004-08-05 Gabanerge modulatoren ATE456558T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49517903P 2003-08-14 2003-08-14
US57438404P 2004-05-25 2004-05-25
PCT/EP2004/008767 WO2005016892A1 (en) 2003-08-14 2004-08-05 Gabanergic modulators

Publications (1)

Publication Number Publication Date
ATE456558T1 true ATE456558T1 (de) 2010-02-15

Family

ID=34198028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04763813T ATE456558T1 (de) 2003-08-14 2004-08-05 Gabanerge modulatoren

Country Status (14)

Country Link
US (1) US7365211B2 (de)
EP (1) EP1656353B1 (de)
JP (1) JP2007502257A (de)
KR (1) KR100742014B1 (de)
AR (1) AR045255A1 (de)
AT (1) ATE456558T1 (de)
AU (1) AU2004265101B2 (de)
BR (1) BRPI0413540A (de)
CA (1) CA2535406A1 (de)
DE (1) DE602004025354D1 (de)
MX (1) MXPA06001660A (de)
RU (1) RU2376292C2 (de)
TW (1) TW200524878A (de)
WO (1) WO2005016892A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
GT200500208A (es) * 2004-08-03 2006-03-02 Indazoles ùtiles para tratar enfermedades cardiovasculares
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
ES2333680T3 (es) * 2006-04-11 2010-02-25 F. Hoffmann-La Roche Ag Moduladores heterociclicos del receptor selectivo del subtipo de gaba alfa.
BRPI0720849A2 (pt) * 2006-12-22 2014-03-11 Hoffmann La Roche Processos para a preparação de (3r,4r)-n-(4-clorofenil)-1-(2,2-difluoretil)-n'-(2-flúor-4- (2-oxo-1-(2h)-piridinil)fenil]-3,4-pirrolidinadicarboxam ida
PT3088384T (pt) * 2007-05-15 2019-03-22 Aventis Agriculture Compostos de ariloazol-2-il-cianoetilamino, método de fabrico e seu método de utilização
AR074024A1 (es) 2008-11-14 2010-12-15 Merial Ltd Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria
CN102325765B (zh) 2009-02-06 2014-12-24 杨森制药公司 作为γ-分泌酶调节剂的取代的双环杂环化合物
EA019702B1 (ru) 2009-05-07 2014-05-30 Янссен Фармасьютикалз, Инк. Замещенные производные индазола и азаиндазола в качестве модуляторов гамма-секретазы
WO2011006903A1 (en) 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
PH12012501381A1 (en) 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
EP2582666B1 (de) * 2010-06-16 2014-08-13 Purdue Pharma L.P. Arylsubstituierte indole und ihre verwendung als kalzium-kanal-blocker
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
CN103874702B (zh) 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
JP2014034523A (ja) * 2012-08-07 2014-02-24 Manac Inc モノまたはジハロゲノピリジルアミン類の製造方法
US8822689B2 (en) 2012-09-19 2014-09-02 Merial Limited Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
WO2014061676A1 (ja) * 2012-10-16 2014-04-24 武田薬品工業株式会社 複素環化合物
WO2014096212A1 (en) 2012-12-20 2014-06-26 Janssen Pharmaceutica Nv NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
KR102171710B1 (ko) 2013-01-17 2020-10-30 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
WO2019200061A1 (en) * 2018-04-11 2019-10-17 The General Hospital Corporation Anesthetic compounds
EP3810610A1 (de) 2018-05-18 2021-04-28 Incyte Corporation Kondensierte pyrimidinderivate als a2a/a2b-inhibitoren
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11911364B2 (en) 2018-09-25 2024-02-27 Pepticom Ltd. Positive allosteric modulators of GABAA receptor
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
CN116462628A (zh) * 2022-01-12 2023-07-21 联化科技新材(台州)有限公司 一种2-溴-5-氨基吡啶的制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0898566T3 (da) * 1996-04-19 2003-03-03 Akzo Nobel Nv Substituerede benzylaminer og anvendelse deraf til behandling af depression
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ スクイブ カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
GB0008696D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic agents
AU2001267963A1 (en) * 2000-06-30 2002-01-08 Light Eye Developments Limited Improved dynamo
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
WO2002020492A1 (en) * 2000-09-06 2002-03-14 Neurogen Corporation Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
JP4401298B2 (ja) * 2002-12-02 2010-01-20 エフ.ホフマン−ラ ロシュ アーゲー Crfアンタゴニストとしてのインダゾール誘導体

Also Published As

Publication number Publication date
BRPI0413540A (pt) 2006-10-10
AU2004265101B2 (en) 2009-06-11
AU2004265101A1 (en) 2005-02-24
RU2006107438A (ru) 2007-09-20
MXPA06001660A (es) 2006-04-28
EP1656353B1 (de) 2010-01-27
DE602004025354D1 (de) 2010-03-18
RU2376292C2 (ru) 2009-12-20
JP2007502257A (ja) 2007-02-08
KR20060037440A (ko) 2006-05-03
KR100742014B1 (ko) 2007-07-23
EP1656353A1 (de) 2006-05-17
WO2005016892A1 (en) 2005-02-24
US7365211B2 (en) 2008-04-29
TW200524878A (en) 2005-08-01
CA2535406A1 (en) 2005-02-24
US20050101614A1 (en) 2005-05-12
AR045255A1 (es) 2005-10-19

Similar Documents

Publication Publication Date Title
DE602004025354D1 (de) Gabanerge modulatoren
DE602004026540D1 (de) Kurbelwellenmomentmodulator
ATE363383T1 (de) Schlingenware
FI20020800A7 (fi) Modulaattori
DE502004011955D1 (de) Doppelkuppllungsgetriebe
DE502004001683D1 (de) Kabelführung
DE502004010381D1 (de) Um
DE60319796D1 (de) tsdetektion
FR2862675B1 (fr) Defonceuse
DK2447252T3 (da) Theramuteinmodulatorer
DE60331697D1 (de) Verzögerungszeitdiskriminator
DE602004000258D1 (de) Einhebelwasserarmatur
DE602004018247D1 (de) Modulator
DE602004013661D1 (de) Spritzgiessnadelverschlussbuchse
DE502004002978D1 (de) N-biarylamide
DK1581307T3 (da) Irs modulatorer
DE602004010064D1 (de) Freilaufkupplungsfeder
DE602004009257D1 (de) Bremsschlauchanordung
DE602004009212D1 (de) Fluidstrahlbohrwerkzeug
DE602004025937D1 (de) 2-aminobenzoylderivate
DE50305802D1 (de) Stanz-prägeniet
FR2864125B1 (fr) Caillebotis
DE502004007959D1 (de) Prolinylarylacetamide
DE20317661U1 (de) Faltkleiderschrank
DE502004001283D1 (de) Umsymmetrieranordnung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties